• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Perioperative management for patients with hereditary angioedema.遗传性血管性水肿患者的围手术期管理
Allergy Rhinol (Providence). 2015 Jan;6(1):50-5. doi: 10.2500/ar.2015.6.0112.
2
Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.美国遗传性血管性水肿预防性治疗的现有选择:基于患者的考虑因素。
Allergy Asthma Proc. 2012 May-Jun;33(3):235-40. doi: 10.2500/aap.2012.33.3573.
3
The prophylactic use of C1 inhibitor in hereditary angioedema patients undergoing invasive surgical procedures: a retrospective study.预防性使用 C1 抑制剂在接受有创手术的遗传性血管性水肿患者中的应用:一项回顾性研究。
Allergy Asthma Clin Immunol. 2014 Apr 23;10(1):17. doi: 10.1186/1710-1492-10-17. eCollection 2014.
4
Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure.每日静脉输注C1酯酶抑制剂浓缩物成功用于治疗一名患有腹水、低血容量性休克、败血症、肾和呼吸衰竭的遗传性血管性水肿患者。
Allergy Asthma Clin Immunol. 2014 Dec 11;10(1):62. doi: 10.1186/s13223-014-0062-9. eCollection 2014.
5
Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.重组人C1酯酶抑制剂在遗传性血管性水肿治疗中的应用
Clin Drug Investig. 2015 Jul;35(7):407-17. doi: 10.1007/s40261-015-0300-z.
6
Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies.遗传性血管性水肿致 C1 酯酶抑制剂缺乏症:基于文献的分析和预防治疗策略的临床评论。
World Allergy Organ J. 2011 Feb;4(2 Suppl):S9-S21. doi: 10.1097/WOX.0b013e31821359a2.
7
Management of dental-oral procedures in patients with hereditary angioedema due to C1 inhibitor deficiency.遗传性血管性水肿患者牙科-口腔操作的管理:C1 抑制剂缺乏症。
J Investig Allergol Clin Immunol. 2013;23(1):1-6.
8
Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.美国遗传性血管性水肿治疗:向国际治疗共识迈进。
Clin Ther. 2012 Mar;34(3):623-30. doi: 10.1016/j.clinthera.2012.02.003. Epub 2012 Mar 2.
9
Diagnosis and screening of patients with hereditary angioedema in primary care.基层医疗中遗传性血管性水肿患者的诊断与筛查
Ther Clin Risk Manag. 2016 May 2;12:701-11. doi: 10.2147/TCRM.S86293. eCollection 2016.
10
Hereditary angioedema: what the gastroenterologist needs to know.遗传性血管性水肿:胃肠病学家需要了解的内容。
Clin Exp Gastroenterol. 2014 Nov 20;7:435-45. doi: 10.2147/CEG.S50465. eCollection 2014.

引用本文的文献

1
The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.国际血管性水肿学会(WAO)/欧洲变态反应和临床免疫学会(EAACI)遗传性血管性水肿管理指南——2021年修订与更新
World Allergy Organ J. 2022 Apr 7;15(3):100627. doi: 10.1016/j.waojou.2022.100627. eCollection 2022 Mar.
2
Clinical manifestations of hereditary angioedema and a systematic review of treatment options.遗传性血管性水肿的临床表现及治疗选择的系统评价。
Laryngoscope Investig Otolaryngol. 2021 Apr 3;6(3):394-403. doi: 10.1002/lio2.555. eCollection 2021 Jun.
3
Capillary leak syndrome and disseminated intravascular coagulation after kidney transplantation in a patient with hereditary angioedema - A case report.遗传性血管性水肿患者肾移植后发生毛细血管渗漏综合征和弥散性血管内凝血——病例报告
Anesth Pain Med (Seoul). 2021 Jan;16(1):75-80. doi: 10.17085/apm.20098. Epub 2021 Jan 27.
4
A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema.遗传性血管性水肿患儿人 C1 抑制剂预防的随机试验。
Pediatr Allergy Immunol. 2019 Aug;30(5):553-561. doi: 10.1111/pai.13060. Epub 2019 May 29.
5
Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings.使用Cinryze®预防儿童遗传性血管性水肿发作:3期试验中期疗效与安全性结果
Int Arch Allergy Immunol. 2017;173(2):114-119. doi: 10.1159/000477541. Epub 2017 Jun 30.
6
Angioedema: Perioperative management.血管性水肿:围手术期管理
SAGE Open Med Case Rep. 2017 Jun 8;5:2050313X17713912. doi: 10.1177/2050313X17713912. eCollection 2017.
7
Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance.用于遗传性血管性水肿管理的自我注射用C1酯酶抑制剂浓缩剂:可用性和患者接受度。
Patient Prefer Adherence. 2016 Sep 7;10:1727-37. doi: 10.2147/PPA.S86379. eCollection 2016.
8
Angioedema: Classification, management and emerging therapies for the perioperative physician.血管性水肿:围手术期医生的分类、管理及新兴治疗方法
Indian J Anaesth. 2016 Aug;60(8):534-41. doi: 10.4103/0019-5049.187776.

本文引用的文献

1
HAE update: determining optimal patient specific therapy.遗传性血管性水肿更新:确定最佳个体化治疗方案。
Allergy Asthma Proc. 2013 Jan-Feb;34(1):7-12. doi: 10.2500/aap.2013.34.3624.
2
WAO Guideline for the Management of Hereditary Angioedema.WAO 遗传性血管性水肿管理指南。
World Allergy Organ J. 2012 Dec;5(12):182-99. doi: 10.1097/WOX.0b013e318279affa.
3
Management of hereditary angioedema with C1-inhibitor concentrate during two successive pregnancies.
Int J Gynaecol Obstet. 2013 Feb;120(2):189-90. doi: 10.1016/j.ijgo.2012.09.009. Epub 2012 Nov 24.
4
C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of life.遗传性血管性水肿发作的 C1 抑制剂治疗:前瞻性患者健康相关生活质量评估。
Allergy Asthma Proc. 2012 Sep-Oct;33(5):427-31. doi: 10.2500/aap.2012.33.3597.
5
An update on hereditary angioedema.遗传性血管性水肿更新。
Curr Opin Pediatr. 2012 Oct;24(5):638-46. doi: 10.1097/MOP.0b013e328357b25e.
6
Hereditary angioedema treatment options: the availability of new therapies.遗传性血管性水肿治疗选择:新疗法的可及性。
Ann Med. 2012 Sep;44(6):523-9. doi: 10.3109/07853890.2012.687833. Epub 2012 Jul 11.
7
Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.美国遗传性血管性水肿预防性治疗的现有选择:基于患者的考虑因素。
Allergy Asthma Proc. 2012 May-Jun;33(3):235-40. doi: 10.2500/aap.2012.33.3573.
8
Successful C1 inhibitor prophylaxis during zenker diverticulum repair in a patient with hereditary angioedema.
Ann Allergy Asthma Immunol. 2012 Feb;108(2):126-8. doi: 10.1016/j.anai.2011.11.011. Epub 2011 Dec 20.
9
Diagnosis and management of hereditary angioedema: an emergency medicine perspective.遗传性血管性水肿的诊断与管理:急诊医学视角
J Emerg Med. 2012 Aug;43(2):391-400. doi: 10.1016/j.jemermed.2011.06.125. Epub 2012 Jan 27.
10
Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety.Cinryze作为美国首个获批用于治疗遗传性血管性水肿的C1抑制剂:获批情况、疗效与安全性。
J Blood Med. 2010;1:163-70. doi: 10.2147/JBM.S9576. Epub 2010 Aug 24.

遗传性血管性水肿患者的围手术期管理

Perioperative management for patients with hereditary angioedema.

作者信息

Williams Anesu H, Craig Timothy J

机构信息

Department of Health Science, Midwestern University, Downers Grove, Illinois, USA.

出版信息

Allergy Rhinol (Providence). 2015 Jan;6(1):50-5. doi: 10.2500/ar.2015.6.0112.

DOI:10.2500/ar.2015.6.0112
PMID:25860171
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4388877/
Abstract

Hereditary angioedema (HAE) is a rare autosomal dominant disease that results from mutations in the C1-esterase inhibitor (C1-INH) gene. HAE is characterized by recurrent episodes of angioedema of the skin (face, extremities, genitalia, trunk), the gastrointestinal tract, and respiratory tract. Symptoms experienced can be debilitating, may impact quality of life, and can be life threatening. Preventing attacks particularly for patients undergoing procedures is critical. Patients with HAE may now treat acute attacks or prevent attacks with medications that have recently become available in the United States; however, these same medications can be used for perioperative management for patients undergoing medical, surgical, and dental procedures. Periprocedural planning is important for patients to reduce the incidence of acute attacks. Education is critical and increasing awareness of short-term prophylaxis options will allow providers to develop an appropriate action plan for their patients. The goal of this review is to increase awareness for HAE treating physicians, surgeons, anesthesia, and emergency room physicians by examining the available treatment options, researching the literature, and summarizing available data for periprocedural management. The availability of treatment options has increased over the past few years, expanding options for physicians and patients living with HAE and improve safety during the perioperative period and at the time of other procedures.

摘要

遗传性血管性水肿(HAE)是一种罕见的常染色体显性疾病,由C1酯酶抑制剂(C1-INH)基因突变引起。HAE的特征是皮肤(面部、四肢、生殖器、躯干)、胃肠道和呼吸道反复出现血管性水肿发作。所经历的症状可能使人衰弱,可能影响生活质量,并且可能危及生命。对于正在接受手术的患者来说,预防发作尤为关键。患有HAE的患者现在可以使用美国最近上市的药物来治疗急性发作或预防发作;然而,这些相同的药物也可用于接受医疗、外科和牙科手术患者的围手术期管理。围手术期规划对于患者减少急性发作的发生率很重要。教育至关重要,提高对短期预防方案的认识将使医疗服务提供者能够为其患者制定适当的行动计划。本综述的目的是通过研究可用的治疗选择、查阅文献以及总结围手术期管理的现有数据,提高HAE治疗医生、外科医生、麻醉医生和急诊室医生的认识。在过去几年中,治疗选择有所增加,为患有HAE的医生和患者提供了更多选择,并提高了围手术期及其他手术期间的安全性。